Premature BirthNCT06063122
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
A study testing smallTalk NICU Active in people with Premature Birth, run by Thrive Neuromedical, LLC at 2 sites in United States.
Trial summary
The goal of this clinical study is to test a new, novel medical device designed to improve speech sound differentiation among hospitalized preterm infants. The device is designed to be used at an age equivalent to 32 weeks of gestation or older and to integrate readily into clinical practice for use by nurses and… Read more about this study
- Who is it for?
- Ages 32 to 35 weeksHealthy volunteers can take part
- Conditions the study is for
- Premature Birth
- What is being tested?
- smallTalk NICU Active
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 203 participants
- Where
- 2 sitesUnited States
- Study dates
- 8 Mar 2024to 1 Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 32 to 35 weeks
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- CGA 32 0/7-35 0/7 weeks at study start, and GA 35 0/7 weeks at birth
Who cannot join
- Ventilation using an endotracheal tube, major congenital malformations, family history of genetic hearing loss, and use of sedative/seizure medications (medications potentially masking ERP measured sensory processing) and severe white matter injury as it increases the likelihood of hearing deficits.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Emory University
Atlanta, Georgia, 30322
Nathalie Maitre, MD, 404-785-2000, nathalie.linda.maitre@emory.edu
- Not yet recruiting
Thrive Neuromedical, LLC
Chagrin Falls, Ohio, 44023
Dean Koch, 440-289-3656, dean@smalltalk.tech
About this study
The goal of this clinical study is to test a new, novel medical device designed to improve speech sound differentiation among hospitalized preterm infants. The device is designed to be used at an age equivalent to 32 weeks of gestation or older and to integrate readily into clinical practice for use by nurses and therapists staffing Level II to Level IV NICUs. Preterm born infants are at high risk for neurosensory impairments and developmental delays. In the NICU, infants are often deprived of infant-directed parental speech because of numerous challenges to parental visitation, resulting in reduced differentiation of speech sounds, altered brain structure and poor language outcomes.
The study will explore the effectiveness of a novel medical device designed for infant learning through contingent sucking on a pacifier equipped with a sensor for suck pressure/timing, connected to a speaker that delivers mother's voice.
The study will test the hypothesis that there will be a greater response difference between speech sounds on EEG, for infants receiving the suck-contingent mother's voice intervention than for infants hearing the same amount of non-contingent mother's voice from a speaker device.
Read the detailed description
Every year in the United States, approximately 10% of infants are born preterm, impacting nearly 400,000 families in the US alone. These infants often experience significant cognitive and language delays in early childhood, with negative implications on social and academic function at school age and beyond. Complex higher-order functions, such as language, build on early, more basic neural processes that lay the foundation for later connections and systems. A fundamental neural processing function necessary for the development of cognition and receptive language is the early ability to differentiate speech sounds from each other (above hearing, a simpler perception of sound). In preterm infants, speech sound processing is frequently deficient relative to full-term peers at discharge from the neonatal intensive care unit (NICU) and is associated with worse outcomes at two years of age. Time spent in the NICU after birth does not compensate for atypical speech sound processing, and by early childhood, many preterm infants require targeted therapies. Currently, no technological intervention addresses the problem of preterm infants' poor speech sound differentiation during NICU hospitalization, when the greatest potential for improving this basic neural process exists.
Root of the problem: Contributing to poor speech sound processing of preterm infants is an atypical NICU auditory environment, experienced during a time of neural vulnerability and critical developmental phases. The NICU environment is rich in machine sounds or human voices which, unfiltered by the uterine environment, are often above recommended volume levels. Conversely, the NICU is poor in sounds that would normally wire developing connections in the newborn brain, such as human voices in a natural environment. The optimal auditory stimulus for infants after birth would be their parents' voices, at low volume and addressed in infant-directed and responsive patterns. However, despite supportive NICU policies, few parents can consistently be present to provide this voice intervention, due to social, geographic, and economic imperatives. Social and psychological determinants of health further aggravate the problem.
Solutions: Providing infants with their parents' recorded voice when they are awake, physiologically stable, and receptive can help their developing auditory system receive appropriate experiences. In addition, if the voice is: 1) infant-directed; 2) at volumes and rhythms calibrated against naturally occurring stimuli; and 3) contingently provided upon infant request (consistently delivered after the same easy action, within a very brief timeframe), the conditions of optimal learning of speech sound in developing humans are met.
Challenges to the design of effective interventions: Safety concerns exist in placing most speaker devices in incubators and cribs, namely infection risks from devices that cannot be fully sanitized and provision of loud/unfiltered sounds at times when an infant is not receptive, causing physiologic instability. Efficacy concerns exist regarding the provision of uncalibrated content when the neural circuitry of auditory processing is immature and inefficient. In addition, active learning has been demonstrated in infants and young children as far superior for brain plasticity and development compared to passive exposure to recorded material. Finally, measuring intervention effects in preverbal infants is inaccurate using standard behavioral assessments.
In this investigation, the clinical study team will leverage strong evidence that shows reading and singing (calibrated against natural environment occurrences) are beneficial for cognitive and language development in preterm infants when mother's voice is directed to the infant upon request. The technology investigated is designed to support infants in the NICU while engaging their mothers. The technology is designed to optimize learning experiences by controlling the level and duration of the intervention; The clinical study team partners with NICU nursing teams to schedule delivery of mother's voice during stable and receptive states. The intervention device is designed to ensure learning through contingent sucking on a pacifier equipped with a sensor for suck pressure/timing, connected to a speaker that delivers mother's voice. The technology is proven sanitizable, to meet NICU infection-control standards. Through this design, parents are empowered to help their children even when they do have the means, ability, or time to stay in the hospital every day - this technology supports NICUs in providing both excellence and justice in care. Because this study includes a population with higher diversity of social determinants of health compared to national standards, and because of a family support process already in place at the enrolling study sites, the clinical study team has made efforts to ensure participation in research for all, equally, improving the generalizability of the resulting findings. Finally, the clinical study team measures outcomes objectively, using brain-based (EEG) measures of speech sound processing. These measures have high construct validity in preterm infants for the study purposes because they: (1) are elicited consistently across the spectrum of prematurity and settings (2) reflect degree of maturity of language processing (3) are highly predictive of receptive language scores in the first two years, and (4) are responsive to treatment with a 3-week contingent-voice paradigm. The study is designed to demonstrate the efficacy of the technology in a randomized controlled trial using rigorous protocols; the study design respects standard care that most often incorporates infant's passive listening to parent-recorded voice (providing a more conservative measurement of the intervention's effect than if it were compared it to no exposure at all); the study design investigates potential effects of the NICU environment such as room types (single vs. open bay) and ambient noise. The study aims follow.
- The study will test the hypothesis that there will be a greater response difference between speech sounds on EEG, for infants receiving the suck-contingent mother's voice intervention than for infants hearing the same amount of non-contingent mother's voice.
- The study will test whether the intervention effect size increases when NICU background noise is lower.
- The study will explore whether the intervention effect size varies by NICU room type.
- Conditions
- Premature Birth
- Being tested
- smallTalk NICU Active
- Keywords
- preterm, premature, NICU, neonatal
- Medical subject headings
- Premature Birth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
smallTalk NICU ActiveDevice
The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
| Study group | Role | What they receive |
|---|---|---|
| Control Group: Non-contingent exposure to recorded mother's voice | Sham comparator | Participants will receive 20 minutes of non-contingent recorded mother' voice during two 20-minute sessions, with a maximum of 2 sessions per day. Recordings are played through the smallTalk speaker device in passive mode, which limits play time to 20-minute exactly and volume to 45 dB in the A-weighted scale as per American Academy of Pediatrics recommendations. For these sessions, the therapist will remain at bedside with the infant and the device, as if they were administering the intervention. Nurses do not typically remain at bedside for the procedure due to workload issues and the low risk of the intervention. Receives: Device: smallTalk NICU Active |
| Intervention Group: Contingent exposure to recorded mother's voice | Experimental | Participants will receive 20 minutes of contingent recorded mother' voice also at 45 dBA, during two 20-minute sessions, with a maximum of 2 sessions per day. The smallTalk Active system integrates a wireless, lightweight and sealed sensor unit that securely fits into a Philips NICU Soothie pacifier. The speaker device is factory set to communicate constantly with the sensor unit, and to only deliver a predetermined 10 seconds of recorded parent's voice upon detection of a suck that meets a pressure threshold, which is automatically set by the speaker device. Receives: Device: smallTalk NICU Active |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensory processing measurement by ERP recording
A high-density array of 128 electrodes embedded in soft sponges (high-density 64-electrode waveguard™ net, ANT Neuro, Hengelo, Netherlands) will be used to record ERPs with a sampling rate of 1000 Hz, filters set to 0.1-400 Hz. Recording of brainwaves will be controlled by eego™mylab system (v. 9.2, ANT Neuro, Hengelo, Netherlands). E-Prime (v. 4.0, PST, Inc., Pittsburgh, PA) software will control stimulus delivery. The stimuli will be presented at 60 dBA. The ERP speech sound paradigm included a computer-generated woman's voicing one of six syllables (/ba/, /da/, /ga/, /bu/, /du/, /gu/) randomly and at random intertrial intervals for a total of 25 trials per syllables over 7-10 minutes. Inter-trial intervals will be varied between 1600ms and 2600ms. All stimuli are presented thus to prevent habituation.
Measured: Initial ERP Test is performed 2 days prior to intervention. Intervention timeframe is 20 sessions across 3 weeks. ERP Test is repeated within 24 hours of the last session.
Secondary outcomes (2)
Intervention effect size impact by NICU background noise
We will test whether the effect size of the between-treatment-group, pretest-adjusted effect will vary by amount of background noise, favoring lower background noise.
During each session, a sound level meter will record sound amplitude exposure at the baby's head. Sound levels will be logged onto a built-in SD card at 15 min intervals and downloaded after a 24-hour period. Measurements will occur every 3 days. Average sound exposure will be calculated from all measurements over the course of the intervention.
Measured: Within 3 months of the full enrollment of study, we will assess if the primary outcome measure is impacted by the level of NICU background noise.
Intervention effect size by NICU room type (private or semi-private/open bay)
This aim is only exploratory and will investigate the possibility that the between-treatment-group, pretest-adjusted effect size will vary by the room setting in which mother's voice exposure occurred.
Measured: Within 3 months of the full enrollment of study, we will assess if the primary outcome measure is impacted by the NICU room type
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2023
- Study start8 Mar 2024
- Primary completion31 Jan 2026 (estimated)
- Study completion1 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Premature BirthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Controlled Trial with double blind
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 203 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Thrive Neuromedical, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD), Emory University
- Responsible party
- Sponsor
- Investigators
- Dean Koch, Principal investigator, Thrive Neuromedical, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06063122
- Sponsor's protocol ID
- 202401
- Other IDs
- 1R44DC020684-01A1
- Status last verified
- Sep 2025
- First submitted
- 30 Aug 2023
- Last updated
- 10 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: All reasonable requests from qualified scientists for unique research resources (protocols and expertise) developed with NIH funds for research purposes will be honored.
Publications
Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman RE, Butler AS, editors. Preterm Birth: Causes, Consequences, and Prevention. Washington (DC): National Academies Press (US); 2007. Available from http://www.ncbi.nlm.nih.gov/books/NBK11362/
PubMed 20669423
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- ClinicalTrials.gov ID
- NCT06063122
- Acronym / sponsor ID
- 202401
- Conditions
- Premature Birth
- Keywords
- preterm, premature, NICU, neonatal
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 203 participants (estimated)
- Lead sponsor
- Thrive Neuromedical, LLCIndustry (pharma, biotech, devices)
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD), Emory University
- Study start
- 8 Mar 2024 (actual)
- Primary completion
- 31 Jan 2026 (estimated)
- Study completion
- 1 Feb 2026 (estimated)
- First posted
- 2 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical study is to test a new, novel medical device designed to improve speech sound differentiation among hospitalized preterm infants. The device is designed to be used at an age equivalent to 32 weeks of gestation or older and to integrate readily into clinical practice for use by nurses and therapists staffing Level II to Level IV NICUs. Preterm born infants are at high risk for neurosensory impairments and developmental delays. In the NICU, infants are often deprived of infant-directed parental speech because of numerous challenges to parental visitation, resulting in reduced differentiation of speech sounds, altered brain structure and poor language outcomes.
The study will explore the effectiveness of a novel medical device designed for infant learning through contingent sucking on a pacifier equipped with a sensor for suck pressure/timing, connected to a speaker that delivers mother's voice.
The study will test the hypothesis that there will be a greater response difference between speech sounds on EEG, for infants receiving the suck-contingent mother's voice intervention than for infants hearing the same amount of non-contingent mother's voice from a speaker device.
Detailed description
Every year in the United States, approximately 10% of infants are born preterm, impacting nearly 400,000 families in the US alone. These infants often experience significant cognitive and language delays in early childhood, with negative implications on social and academic function at school age and beyond. Complex higher-order functions, such as language, build on early, more basic neural processes that lay the foundation for later connections and systems. A fundamental neural processing function necessary for the development of cognition and receptive language is the early ability to differentiate speech sounds from each other (above hearing, a simpler perception of sound). In preterm infants, speech sound processing is frequently deficient relative to full-term peers at discharge from the neonatal intensive care unit (NICU) and is associated with worse outcomes at two years of age. Time spent in the NICU after birth does not compensate for atypical speech sound processing, and by early childhood, many preterm infants require targeted therapies. Currently, no technological intervention addresses the problem of preterm infants' poor speech sound differentiation during NICU hospitalization, when the greatest potential for improving this basic neural process exists.
Root of the problem: Contributing to poor speech sound processing of preterm infants is an atypical NICU auditory environment, experienced during a time of neural vulnerability and critical developmental phases. The NICU environment is rich in machine sounds or human voices which, unfiltered by the uterine environment, are often above recommended volume levels. Conversely, the NICU is poor in sounds that would normally wire developing connections in the newborn brain, such as human voices in a natural environment. The optimal auditory stimulus for infants after birth would be their parents' voices, at low volume and addressed in infant-directed and responsive patterns. However, despite supportive NICU policies, few parents can consistently be present to provide this voice intervention, due to social, geographic, and economic imperatives. Social and psychological determinants of health further aggravate the problem.
Solutions: Providing infants with their parents' recorded voice when they are awake, physiologically stable, and receptive can help their developing auditory system receive appropriate experiences. In addition, if the voice is: 1) infant-directed; 2) at volumes and rhythms calibrated against naturally occurring stimuli; and 3) contingently provided upon infant request (consistently delivered after the same easy action, within a very brief timeframe), the conditions of optimal learning of speech sound in developing humans are met.
Challenges to the design of effective interventions: Safety concerns exist in placing most speaker devices in incubators and cribs, namely infection risks from devices that cannot be fully sanitized and provision of loud/unfiltered sounds at times when an infant is not receptive, causing physiologic instability. Efficacy concerns exist regarding the provision of uncalibrated content when the neural circuitry of auditory processing is immature and inefficient. In addition, active learning has been demonstrated in infants and young children as far superior for brain plasticity and development compared to passive exposure to recorded material. Finally, measuring intervention effects in preverbal infants is inaccurate using standard behavioral assessments.
In this investigation, the clinical study team will leverage strong evidence that shows reading and singing (calibrated against natural environment occurrences) are beneficial for cognitive and language development in preterm infants when mother's voice is directed to the infant upon request. The technology investigated is designed to support infants in the NICU while engaging their mothers. The technology is designed to optimize learning experiences by controlling the level and duration of the intervention; The clinical study team partners with NICU nursing teams to schedule delivery of mother's voice during stable and receptive states. The intervention device is designed to ensure learning through contingent sucking on a pacifier equipped with a sensor for suck pressure/timing, connected to a speaker that delivers mother's voice. The technology is proven sanitizable, to meet NICU infection-control standards. Through this design, parents are empowered to help their children even when they do have the means, ability, or time to stay in the hospital every day - this technology supports NICUs in providing both excellence and justice in care. Because this study includes a population with higher diversity of social determinants of health compared to national standards, and because of a family support process already in place at the enrolling study sites, the clinical study team has made efforts to ensure participation in research for all, equally, improving the generalizability of the resulting findings. Finally, the clinical study team measures outcomes objectively, using brain-based (EEG) measures of speech sound processing. These measures have high construct validity in preterm infants for the study purposes because they: (1) are elicited consistently across the spectrum of prematurity and settings (2) reflect degree of maturity of language processing (3) are highly predictive of receptive language scores in the first two years, and (4) are responsive to treatment with a 3-week contingent-voice paradigm. The study is designed to demonstrate the efficacy of the technology in a randomized controlled trial using rigorous protocols; the study design respects standard care that most often incorporates infant's passive listening to parent-recorded voice (providing a more conservative measurement of the intervention's effect than if it were compared it to no exposure at all); the study design investigates potential effects of the NICU environment such as room types (single vs. open bay) and ambient noise. The study aims follow.
- The study will test the hypothesis that there will be a greater response difference between speech sounds on EEG, for infants receiving the suck-contingent mother's voice intervention than for infants hearing the same amount of non-contingent mother's voice.
- The study will test whether the intervention effect size increases when NICU background noise is lower.
- The study will explore whether the intervention effect size varies by NICU room type.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized Controlled Trial with double blind
| Arm | Type | Receives |
|---|---|---|
| Control Group: Non-contingent exposure to recorded mother's voice | Sham comparator | Device: smallTalk NICU ActiveParticipants will receive 20 minutes of non-contingent recorded mother' voice during two 20-minute sessions, with a maximum of 2 sessions per day. Recordings are played through the smallTalk speaker device in passive mode, which limits play time to 20-minute exactly and volume to 45 dB in the A-weighted scale as per American Academy of Pediatrics recommendations. For these sessions, the therapist will remain at bedside with the infant and the device, as if they were administering the intervention. Nurses do not typically remain at bedside for the procedure due to workload issues and the low risk of the intervention. |
| Intervention Group: Contingent exposure to recorded mother's voice | Experimental | Device: smallTalk NICU ActiveParticipants will receive 20 minutes of contingent recorded mother' voice also at 45 dBA, during two 20-minute sessions, with a maximum of 2 sessions per day. The smallTalk Active system integrates a wireless, lightweight and sealed sensor unit that securely fits into a Philips NICU Soothie pacifier. The speaker device is factory set to communicate constantly with the sensor unit, and to only deliver a predetermined 10 seconds of recorded parent's voice upon detection of a suck that meets a pressure threshold, which is automatically set by the speaker device. |
Who may qualify
- Ages
- 32 to 35 weeks
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- CGA 32 0/7-35 0/7 weeks at study start, and GA 35 0/7 weeks at birth
Key exclusion criteria (1 listed)
- Ventilation using an endotracheal tube, major congenital malformations, family history of genetic hearing loss, and use of sedative/seizure medications (medications potentially masking ERP measured sensory processing) and severe white matter injury as it increases the likelihood of hearing deficits.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| smallTalk NICU ActiveThe novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold. | Device | Control Group: Non-contingent exposure to recorded mother's voice, Intervention Group: Contingent exposure to recorded mother's voice |
Primary outcome
Sensory processing measurement by ERP recording
Time frame: Initial ERP Test is performed 2 days prior to intervention. Intervention timeframe is 20 sessions across 3 weeks. ERP Test is repeated within 24 hours of the last session.
A high-density array of 128 electrodes embedded in soft sponges (high-density 64-electrode waveguard™ net, ANT Neuro, Hengelo, Netherlands) will be used to record ERPs with a sampling rate of 1000 Hz, filters set to 0.1-400 Hz. Recording of brainwaves will be controlled by eego™mylab system (v. 9.2, ANT Neuro, Hengelo, Netherlands). E-Prime (v. 4.0, PST, Inc., Pittsburgh, PA) software will control stimulus delivery. The stimuli will be presented at 60 dBA. The ERP speech sound paradigm included a computer-generated woman's voicing one of six syllables (/ba/, /da/, /ga/, /bu/, /du/, /gu/) randomly and at random intertrial intervals for a total of 25 trials per syllables over 7-10 minutes. Inter-trial intervals will be varied between 1600ms and 2600ms. All stimuli are presented thus to prevent habituation.
2 secondary outcomes
Intervention effect size impact by NICU background noise
Time frame: Within 3 months of the full enrollment of study, we will assess if the primary outcome measure is impacted by the level of NICU background noise.
Intervention effect size by NICU room type (private or semi-private/open bay)
Time frame: Within 3 months of the full enrollment of study, we will assess if the primary outcome measure is impacted by the NICU room type
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2025.
- Background: PubMed 20669423Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman RE, Butler AS, editors. Preterm Birth: Causes, Consequences, and Prevention. Washington (DC): National Academies Press (US); 2007. Available from http://www.ncbi.nlm.nih.gov/books/NBK11362/
- World Health Organization report: Born Too Soon: Decade of Action on Preterm BirthLink provided by the sponsor.
- March of Dimes Report: Long Term Health Effects of Preterm BirthLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. All reasonable requests from qualified scientists for unique research resources (protocols and expertise) developed with NIH funds for research purposes will be honored.
Related trials for Premature Birth
Not yet recruiting
nCPAP-NAVA-Backup Versus Standard nCPAP for Severe Apnea in Preterm Infants ≤28 Weeks
Apnea of Prematurity
Recruiting
Study of the Influence of Intraperitoneal Insufflation of CO2 by Laparoscopy on the Short-term Evolution of Premature Infants With Ulcerative Necrotizing Enterocolitis
Preterm Birth, Enterocolitis, Necrotizing
RecruitingObservational study
Multidimensional Dynamic Early Warning System for Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study
NEC - Necrotizing Enterocolitis
Recruiting
Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)
Premature Infants, Bronchopulmonary Dysplasia
RecruitingObservational study
Growing Little PEAPODS Study
Premature Birth, Premature Infant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dean Koch principal investigator
Thrive Neuromedical, LLC
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing smallTalk NICU Active in people with Premature Birth, run by Thrive Neuromedical, LLC at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dean Koch (440-289-3656, dean@smalltalk.tech), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensory processing measurement by ERP recording (time frame: Initial ERP Test is performed 2 days prior to intervention. Intervention timeframe is 20 sessions across 3 weeks. ERP Test is repeated within 24 hours of the last session.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06063122, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.